1Y Close · As of Aug 26, 2026
CKD Bio operates in the Pharmaceuticals sector.
Legal name: CKD Bio Corp.
In fiscal year 2022, CKD Bio (063160) reported revenue of 156.0 billion KRW, up 9.7% from 142.2 billion KRW a year earlier.
Operating profit was -14.8 billion KRW and net income was -16.7 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 77.7 billion KRW, with a P/B of 0.61.
These figures can be verified in the DART filing (receipt no. 20260318001214).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2022 | 156.0B | -14.8B | -16.7B |
| 2021 | 142.2B | -11.4B | -6.6B |
| 2020 | 124.6B | 7.6B | 6.2B |
Recent Filings
Material Business Matters
Semi-Annual Report (2026.06)
Operating (Preliminary) Earnings (Fair Disclosure)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: No treasury stock filings.
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-14 | Material Business Matters |
| 2026-08-14 | Semi-Annual Report (2026.06) |
| 2026-07-31 | Operating (Preliminary) Earnings (Fair Disclosure) |